Eli Lilly (LLY, Financial) announced detailed findings from its three-year Phase 3 SURMOUNT-1 clinical trial, highlighting the long-term benefits of its obesity drug Wegovy and type 2 diabetes medication Ozempic, both containing the active ingredient tirzepatide.
The study revealed that individuals taking a 15 mg dose, the highest in the trial, experienced an average weight reduction of 22.9%. Across all tested doses, tirzepatide significantly correlated with a 94% reduced risk in diabetes progression compared to a placebo group.
Around 1,000 pre-diabetic participants, classified as obese or overweight, were randomly assigned to receive one of three doses or a placebo. Eli Lilly reported that, in absolute terms, 99% of participants taking tirzepatide did not develop diabetes over the three years.
The SURMOUNT-1 results build upon earlier data released by the company, reinforcing the drug's potential in managing obesity and diabetes risk.
